Literature DB >> 12360407

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

Marion MacFarlane1, Nicholas Harper, Roger T Snowden, Martin J S Dyer, Georgina A Barnett, J Howard Pringle, Gerald M Cohen.   

Abstract

Primary B cells from B cell chronic lymphocytic leukaemia (B-CLL) were resistant to the novel selective cytotoxic agent, TNF-related apoptosis-inducing ligand (TRAIL). Low levels of the death-inducing TRAIL receptors, TRAIL-R1 and TRAIL-R2 but not the putative 'decoy' receptors, TRAIL-R3 and TRAIL-R4, were expressed on the surface of B-CLL cells. Resistance to TRAIL was upstream of caspase-8 activation, as little or no caspase-8 was processed in TRAIL-treated B-CLL cells. Low levels of a TRAIL death-inducing signalling complex (DISC) were formed in these cells, accompanied by the recruitment of endogenous FADD, caspase-8 and c-FLIP(L) but not c-FLIP(S). Both caspase-8 and c-FLIP(L) were cleaved to form two stable intermediates of approximately 43 kDa, which remained associated with the DISC. Caspase-8 was not further processed to its active heterotetramer. Thus the resistance of B-CLL cells to TRAIL may be due partly to low surface expression of the death receptors resulting in low levels of DISC formation and also to the high ratio of c-FLIP(L) to caspase-8 within the DISC, which would prevent further activation of caspase-8. Our results highlight the possibility of sensitising B-CLL cells to TRAIL by modulation of c-FLIP levels or by upregulation of surface expression of death receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360407     DOI: 10.1038/sj.onc.1205853

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Apoptosis and disease: a life or death decision.

Authors:  Marion MacFarlane; Ann C Williams
Journal:  EMBO Rep       Date:  2004-06-25       Impact factor: 8.807

2.  Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax.

Authors:  Subash C Gupta; Simone Reuter; Kanokkarn Phromnoi; Byoungduck Park; Padmanabhan S Hema; Mangalam Nair; Bharat B Aggarwal
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

Review 3.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

4.  Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.

Authors:  Christina Menke; Lianghua Bin; Jacqueline Thorburn; Kian Behbakht; Heide L Ford; Andrew Thorburn
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

5.  Tumor necrosis factor (TNF) receptor-associated factor 7 is required for TNFα-induced Jun NH2-terminal kinase activation and promotes cell death by regulating polyubiquitination and lysosomal degradation of c-FLIP protein.

Authors:  Ivan Scudiero; Tiziana Zotti; Angela Ferravante; Mariangela Vessichelli; Carla Reale; Maria C Masone; Antonio Leonardi; Pasquale Vito; Romania Stilo
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

6.  The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.

Authors:  David M Lucas; Lapo Alinari; Derek A West; Melanie E Davis; Ryan B Edwards; Amy J Johnson; Kristie A Blum; Craig C Hofmeister; Michael A Freitas; Mark R Parthun; Dasheng Wang; Amy Lehman; Xiaoli Zhang; David Jarjoura; Samuel K Kulp; Carlo M Croce; Michael R Grever; Ching-Shih Chen; Robert A Baiocchi; John C Byrd
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

7.  Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.

Authors:  M Russo; C Spagnuolo; S Volpe; A Mupo; I Tedesco; G-L Russo
Journal:  Br J Cancer       Date:  2010-07-20       Impact factor: 7.640

8.  Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis.

Authors:  Ian Sudbery; Anton J Enright; Andrew G Fraser; Ian Dunham
Journal:  BMC Genomics       Date:  2010-03-15       Impact factor: 3.969

9.  Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.

Authors:  Alena Vaculova; Vitaliy Kaminskyy; Elham Jalalvand; Olga Surova; Boris Zhivotovsky
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

Review 10.  FLIP as an anti-cancer therapeutic target.

Authors:  Jin Kuk Yang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.